Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc and keeping the price target at $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including the significant progress Entrada Therapeutics Inc. has made in advancing its clinical pipeline. The company is actively developing multiple candidates for the treatment of Duchenne muscular dystrophy (DMD) across the U.K., EU, and U.S., with several studies in various phases that are expected to yield important data in the coming years. These advancements position Entrada as a potential leader in exon-skipping therapeutics, especially as safety concerns arise with alternative gene therapy approaches for DMD.
Additionally, despite reporting a net loss slightly wider than expected, Entrada maintains a strong financial position with $354 million in cash and equivalents, which should support its operations into the second quarter of 2027. The company’s broad pipeline and strategic focus on neuromuscular and metabolic diseases, alongside its financial stability, underpin the positive outlook and Buy rating from Selvaraju.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 18.5% and a 51.71% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Urogen Pharma, and Cognition Therapeutics.